Endo International plc Class Action Lawsuit
- Company Name
- Endo International plc
- Stock Symbol
- Class Period
- August 8, 2017 to June 10, 2020
- Motion Deadline
- August 18, 2020
- District of New Jersey
The Endo International plc class action lawsuit charges Endo International and certain of its officers with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Endo International securities between August 8, 2017 and June 10, 2020, inclusive (the “Class Period”). The Endo International class action lawsuit was commenced on June 19, 2020 in the District of New Jersey and is captioned Albiges v. Endo International plc, No. 20-cv-07536.
Endo International manufactures and sells generic and branded pharmaceuticals in the United States and internationally, including both generic and branded opioid products. Endo International and its subsidiaries have been substantial manufacturers of opioids in the United States, with the State of New York comprising a significant part of Endo International’s opioid market. Opioid sales constituted a substantial portion of Endo International’s overall revenues, including roughly $403 million of Endo International’s overall revenues in 2012, $657 million of Endo International’s overall revenues in 2014, and $486 million of Endo International’s overall revenues in 2016.
The Endo International class action lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose: (i) the full scope of Endo International’s and/or its subsidiaries’ contributions to the opioid crisis, including, but not limited to, their opioid products’ disproportionately negative impact on New York, one of the most populous states in the United States, as well as the fraud that defendants perpetrated on the New York insurance market; (ii) that part of its contribution to the opioid crisis included Endo International publishing and disseminating false information to healthcare providers regarding the risks and benefits of opioids; (iii) that the foregoing, once revealed, was foreseeably likely to subject Endo International and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to its contribution to the opioid crisis in New York; and (iv) that, as a result, Endo International’s public statements were materially false and misleading at all relevant times.
On June 10, 2020, New York Governor Andrew Cuomo announced that the New York Department of Financial Services had filed administrative charges against Endo International in connection with its role in the opioid crisis, alleging that Endo International fraudulently misrepresented the safety and efficacy of its opioid drugs while minimizing the risk of addiction and other ill effects. On this news, Endo International’s share price fell nearly 15%.
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Endo International securities during the Class Period to seek appointment as lead plaintiff in the Endo International class action lawsuit. A lead plaintiff will act on behalf of all other class members in directing the Endo International class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Endo International class action lawsuit. An investor’s ability to share in any potential future recovery of the Endo International class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Endo International class action lawsuit or have questions concerning your rights regarding the Endo International class action lawsuit, please provide your information here or contact counsel, Michael Albert of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at email@example.com. Lead plaintiff motions for the Endo International class action lawsuit must be filed with the court no later than August 18, 2020.
Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities class action litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations and the media as leading lawyers in the industry.